Products

Catálogo de productos

Fructosyltransferase

Fructosyltransferase: new biocatalyst for the production of fructooligosaccharides from sucrose is an enzyme in the form of powder, produced at high levels in the yeast Pichia pastoris. It can be attractive for several types of productions, from a very simple technological process (in a stirred tank type reactor):


-Producers interested in high quality FOS.
-Sugar producers interested in diversifying their industry towards higher value-added productions (FOS).
-Manufacturers of yoghurts and prebiotic products, with the interest of producing symbiotics, which produce prebiotics in their facilities.

Heberprot-P 75

Heberprot-P product is a pharmaceutical composition containing human recombinant epidermal growth factor (hrecEGF) in an injectable formulation, used by intralesional administration, locally into the wound, for the treatment of diabetic foot ulcer, to accelerate the healing of deep and complex ulcers, either neuropathic or ischemic. In the international arena Heberprot-P has been registered in 23 territories so far. Other registration actions are ongoing in different countries. Commercial Agreements have been signed with foreign companies for the European Union, Colombia, Brazil, Algeria, Mexico, China, Russia and the Gulf and Middle East, among others. Clinical trial phase I for the DFU (Wagner’s classification I & II) under European good clinical practices finished in Cuba with very good results. In addition, a clinical trial phase II finished in Spain, in patients with diabetic foot ulcers in compliance with European GCPs.

Heberon

Heberon Alfa R -Human Recombinat Alpha 2b Interferon- obtained trough recombinat DNA technologies. Heberon Alfa R is an important modifier of the biological response. It offers an excellent response to viral neoplasic and inmunological illnesses and ir also has an antifibrotic effect. Antiviral, antiproliferative and immunomodulator effects

Gavac

Ribosomal protein P0 of Rhipicephalus genus ticks is a promising vaccine candidate. A synthetic peptide of 20 amino acids of an immunogenic region of the protein that is not conserved with respect to their hosts, showed an efficacy of 90 % and 89% as a vaccine against infestation of Rhipicephalus sanguineus in experiments in rabbits and dogs, respectively, causing a drastic decrease in the viability of the ticks. The same peptide used to immunize cattle showed an efficacy of 96 % leading to a significant decrease in recovery and the weight of ticks Rhipicephalus Boophilus microplus and a significant reduction in the weight of egg masses and the hatch percent. These results suggest the promising possibilities of ribosomal protein P0 peptide for the effective control of ectoparasites.

 Download

Heberferon

The formulation (HeberFERON) is a novel stabilized, one vial, pharmaceutical formulation containing IFNs alpha and gamma with improved pharmacodynamics. HeberFERON is stable at 40 0C at least for 24 months. HeberFERON vials containing 3.5-10.0 millions of international units. The in vitro results were confirmed in xerograph animal model suing human Hep-2 tumor cell line (cervix carcinoma) and U87MG (glioblastoma multiform) in nude mice. Preclinical studies of acute toxicity (including intracranial application); local and chronic tolerance demonstrated that the product is safe.

 Download

PEG- Heberon

The introduction in Cuba of PEG- Heberon in combination with ribavirin for the treatment of chronic hepatitis C has allowed to accomplish up to 40% SVR in patients with genotype 1 previously. Active ingredient: interferon alpha- 2b conjugated to polyethylene glycol 40 kDa. PEG- Heberon is indicated for the treatment of chronic hepatitis B and hepatitis C.

Heberprot-P 25

Heberprot-P product is a pharmaceutical composition containing human recombinant epidermal growth factor (hrecEGF) in an injectable formulation, used by intralesional administration, locally into the wound, for the treatment of diabetic foot ulcer, to accelerate the healing of deep and complex ulcers, either neuropathic or ischemic. In the international arena Heberprot-P has been registered in 23 territories so far. Other registration actions are ongoing in different countries. Commercial Agreements have been signed with foreign companies for the European Union, Colombia, Brazil, Algeria, Mexico, China, Russia and the Gulf and Middle East, among others. Clinical trial phase I for the DFU (Wagner’s classification I & II) under European good clinical practices finished in Cuba with very good results. In addition, a clinical trial phase II finished in Spain, in patients with diabetic foot ulcers in compliance with European GCPs.

Herberbiovac

Heberbiovac HB contains a hepatitis B virus surface antigenic protein preparation (HBV). This protein is obtained by means of DNA recombinat procedures. Heberbiovac HB is safe and immnunogenic, besides protecting against type B hepatitis and its sequels, is a good ally for controlling type D hepatitis. Heberbiovac HB production is carried out according to the requirements of the World Health Organization (WHO)

HeberNasvac

HeberNasvac® Vaccine formulation for therapeutic use in patients with chronic infection with hepatitis B virus (HBV). It is composed by the mixture of the surface and nucleocapsid antigens of HBV (HBsAg and HBcAg, respectively) obtained by recombinant methods. HeberNasvac has two presentations, one for intranasal administration and another for subcutaneous injection.

 Download

Heberkinasa

Heberkinasa -recombinant streptokinase- is obtained by means of DNA recombination techniques. Produces a fast lysis of the intracoronary thrombus and prevent the heart ischaemic necrosis. Improves the ventricular function and limits the stroke area. Reduce the risk of lung embolism, facilitating the quick elimination of the embolus

Quimi-Hib

Anti-Haemophilus type B conjugate vaccine obtained from synthetic capsular polysaccharide antigen covalently linked tetanus toxoid. Active immunization against invasive illnesses caused by Haemophilus influenzae type B, in children from 2 months to 5 years of age. Himi-Hib is produced according tot he requirements of the World Health Organization (WHO).

Porvac

Porvac® protein subunit vaccine against classical swine fever virus.
-Eliminates the transmission of the virus between the pigs that live together and from mothers to children.
-Provides early protection after 7 days of vaccination.
-Protection for more than 6 months with 2 doses of the vaccine.
-Allows differentiated diagnoses between carrier and healthy animals

 Download

HeberNem

HeberNem is a biological nematicide, environmentally friendly, which has proven to be an efficient alternative, supplementing the action of chemical nematicides, under a system of integrated pest management. The product has been successfully tested in green houses dedicated to vegetable production in semi-protected crops and plantations of banana and guava. A nationwide mass marketing of bionematocide HeberNem is currently carried out by Permissions Nr. 001/2007 and 050/08 of National Pesticides Registry.

Hebervital

Human GCSF is a glycoproteic hormone produced by monocytes, fibroblasts and endotelial cells. It is obtained by recombinant DNA technology and is the active pharmaceutical ingredient of Hebervital. Hebervital restores the leukocyte blood count. Improves the life quality of cancer patients.